Stocks · News reference
Haemonetics anticipates CSL to transition a portion of its U.S. plasma collection centers to the Company’s devices and disposables, but the scope and timing of implementation have not yet been determined. Accordingly,
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Top Wall Street analysts changed outlook on top names. Baird raised PSN target, BTIG cut WMT target, HSBC raised TX target, Rothschild upgraded EFX, HC Wainwright lowered COCH target, BTIG cut MDXH target, Baird raised ROST target.
Read original at benzingaBaird analyst David Rescott maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $96 to $119.
Read original at benzingaBarrington Research analyst Michael Petusky maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $95 to $118.
Read original at benzingaShares of Haemonetics Corp (NYSE: HAE) are trading higher Tuesday afternoon following news of a significant commercial agreement.
Read original at benzinga